



****REPRESENTATIVE DATASHEET****

Matched-Pair Antibody Set For Neutralization of human Antithrombin (ATIII) in Plasma

Sufficient reagent for **10** determinations

Product #: AT-NU10
Lot #: XXXXX
Expiry Date: XXXXX

1395 Sandhill Drive. Ancaster, Ontario, Canada L9G 4V5
905-304-9896 • 800-903-6020 • fax 905-304-9897

Store at 2 -8°C

For Research Use Only
Not for use in diagnostic procedures.

Description of Antithrombin (ATIII)

Antithrombin, also known as Antithrombin III (ATIII), is a member of the SERPIN family of proteinase inhibitors and the primary inhibitor of thrombin in plasma. It is produced in the liver and circulates in plasma at ~200 µg/ml (~3.5 µM). Antithrombin inhibits a broad spectrum of serine proteases including thrombin, activated forms of factor X, factor IX, factor XI, factor XII, as well as kallikrein, plasmin and urokinase. Enzyme inhibition by antithrombin occurs through proteolytic cleavage at Arg³⁸⁵-Ser³⁸⁶ and subsequent rapid formation of a stable, inactive 1:1 enzyme-antithrombin complex. Heparin has a profound accelerating effect on the inhibitory activity of antithrombin towards some enzymes. The rate of inhibition of thrombin and of activated factor X is increased 1000-fold in the presence of optimal concentrations of heparin, whereas heparin has relatively little effect on the inhibition rate of activated factor XI, activated factor XII and kallikrein. Antithrombin is a single chain molecule with a molecular weight of 59 kDa. Interaction with thrombin results in an SDS-stable binary complex of 96 kDa¹⁻³.

Principle of ATIII Neutralization

Polyclonal sheep antibody to human ATIII is added directly to human plasma and allowed to incubate for 20 minutes. During this time the antibody will bind to and inactivate (neutralize) the ability of ATIII to inhibit thrombin or activated factor X, even in the presence of heparin. Clot-based tests can then be performed on the neutralized sample. To control for the addition of antibody volume and buffer, a control antibody (non-immune sheep IgG, at the same concentration and in the same buffer) is added separately to a duplicate sample and the test is repeated.

References:

1. Damus PS, Rosenberg RD; Antithrombin - Heparin Cofactor; Methods in Enzymology 45, pp 653-669, 1976.
2. Harpel PC; Blood Proteolytic Enzyme Inhibitors: Their Role in Modulating Blood Coagulation and Fibrinolytic Enzyme Pathways; in Hemostasis and Thrombosis, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 738-747, J.B. Lippincott Co., Philadelphia PA, USA, 1982.
3. Griffith MJ, Noyes CM, Church FC; Reactive Site Peptide Structural Similarity between Heparin Cofactor II and Antithrombin III; JBC:260, pp 2218-2225, 1985.

Product Description:

1. **Neutralizing IgG (AT-NU10-T):** One **purple**-capped vial containing 0.1 ml of sheep antibody (IgG) to human ATIII.
2. **Control IgG (AT-NU10-C):** One **white**-capped vial containing 0.1 ml of sheep IgG prepared from non-immune serum for use as a negative control.

Buffer: Both the neutralizing and control IgG have the same protein concentration in 0.02 M HEPES, pH 7.4, 0.01 M Na₃-Citrate, 0.15 M NaCl and 0.02% (w/v) NaN₃.

Storage: Refrigerate at 2-8°C

Test Procedure:

1. Prepare duplicate test tubes, each containing 90 µL of plasma.
2. To the tube labelled test, add 10 µL of test IgG (AT-NU10-T).
3. To the tube labelled control, add 10 µL of control IgG (AT-NU10-C)
4. Mix contents of both tubes and incubate at room temperature for 20 minutes. Both plasmas may be used directly or placed on ice for up to 4 hours.

In the quality control of this product, Thrombin Clot Times were performed as follows:

- 5 µL of 3 U/mL standard heparin (final =0.3 U/mL in plasma)
- 50 µL of normal citrated plasma
- 150 µL of Seegers solution (28 mM Imidazole, 1.7 % (w/v) acacia, 3.7 mM CaCl₂, 57 mM NaCl, pH 7.3)
- 50 µL of human thrombin, adjusted to produce a clot time of approximately 30 seconds in the absence of heparin

Clot times were measured using the ST-4 BIO analyzer (Diagnostica Stago) according to manufacturer's directions.

Technical Notes:

Under the conditions described above, greater than 99% of ATIII in normal plasma is neutralized. This is confirmed using ATIII deficient plasma (product # ATIII-DP).

The above conditions are only intended for use in screening assays of compounds that may exert anticoagulant activity through ATIII. The use of these reagents for quantitative determination of ATIII activity is not recommended.

Related Products:

Cat #: GAAT-IG	Goat anti- ATIII, whole IgG from antiserum
Cat #: GAAT-AP	Goat anti-ATIII, affinity-purified IgG
Cat #: SAAT-IG	Sheep anti- ATIII, whole IgG from antiserum
Cat #: SAAT-AP	Sheep anti-ATIII, affinity-purified IgG
Cat #: SAAT-APHRP	Sheep anti-ATIII, APiGg-peroxidase
Cat #: ATIII-EIA	Paired antibody set for ELISA of ATIII, 5 x 96 wells
Cat #: TAT-EIA	Paired antibody ELISA of Thrombin-ATIII complexes
Cat #: ATIII-DP	Human plasma deficient in ATIII, immune depleted
Cat #: ATHC-DP	Human ATIII & HCII def plasma, immune depleted

Visit our site (www.affinitybiologicals.com) for details.

Limited Warranty: This product is warranted to perform in accordance with its labelling and literature. Affinity Biologicals Inc. disclaims any implied warranty of merchantability or fitness for any other purposes, and in no event will Affinity Biologicals Inc. be liable for any consequential damages arising out of aforesaid express warranty.

Manufactured in Canada by:
AFFINITY BIOLOGICALS INC.
1395 Sandhill Drive
Ancaster, ON CANADA L9G 4V5
Tel: (905) 304-9896
(800) 903-6020
Fax: (905) 304-9897
info@affinitybiologicals.com